FDA OKs Synthon, Breckenridge ANDA for pioglitazone

02/13/2013 | Healio

Synthon Pharmaceuticals and Breckenridge Pharmaceutical have received federal approval for their abbreviated new drug application for pioglitazone in doses of 15, 30 and 45 milligrams. The drug is indicated for type 2 diabetes, along with diet and exercise.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Systems Test - V&V Engineer - 14000008LS
San Jose, CA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
Multiple Locations, SL_Multiple Locations
Director, Antibiotics and Innovation Project
The Pew Charitable Trusts
Washington, DC